Csenge Advisory Group Has $900,000 Position in Novo Nordisk A/S (NYSE:NVO)

Csenge Advisory Group lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 62.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,458 shares of the company's stock after selling 17,649 shares during the period. Csenge Advisory Group's holdings in Novo Nordisk A/S were worth $900,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of NVO. Center for Financial Planning Inc. raised its holdings in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $28,000. Capital Performance Advisors LLP bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $42,000. Albion Financial Group UT raised its holdings in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after purchasing an additional 278 shares in the last quarter. Finally, Sound Income Strategies LLC raised its holdings in shares of Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock valued at $46,000 after purchasing an additional 243 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

NYSE NVO traded up $4.33 during midday trading on Friday, hitting $88.07. The company had a trading volume of 15,117,993 shares, compared to its average volume of 9,263,626. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The stock has a market cap of $395.19 billion, a price-to-earnings ratio of 26.77, a P/E/G ratio of 0.90 and a beta of 0.45. The firm has a fifty day simple moving average of $86.01 and a two-hundred day simple moving average of $108.22. Novo Nordisk A/S has a fifty-two week low of $77.82 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a $0.7874 dividend. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 47.72%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NVO. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a report on Monday, December 23rd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Sunday, December 29th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.